DDrare: Database of Drug Development for Rare Diseases

Searched query = "Progressive supranuclear palsy", "PSP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; 4-benzyl-2-naphtalen-1-yl-1,2,4-thiadiazolidine-3,5-dione; AB1010; ABBV-8E12; AL; AL-108; ASK Nr. 21972; AZP2006 oral solution; Alpha-lipoic acid and L-acetyl carnitine; Anti-Parkinson medication; Antisense oligonucleotide; Azilect; BIIB092; BMS-986168; BMS986168; BOTULINUM TOXIN TYPE A; Balance; Bepranemab; Botulinum toxin type A; Carnitine; CoQ10; Coenzym Q10 Nanodispersion; Coenzym Q10, Ubiquinon, Ubichinon; Coenzyme Q10; Creatine; DaTSCAN™ Ioflupane (123I) Injection; DaTscan; Datscan; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Donepezil; Droxidopa; Emeramide; Exelon 1,5 mg Hartkapseln; Exelon 3,0 mg Hartkapseln; Exelon 6,0 mg Hartkapseln; F-18; F-18 AV 1451; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Fresh Frozen Plasma; GDNF & Synchro Med Infusion System; Gold; Hydrogen; Leucine; Lipoic acid; Lithium; MASITINIB MESYLATE; Masitinib; Masitinib 100mg; Masitinib 200mg; Masitinib mesylate; N1,N3-BIS(2-MERCAPTOETHYL) ISOPHTHALAMIDE; NBMI; NP031112; NP031112 600mg; NP031112 800mg; NT 101; Niacinamide; Nitrogen; Other: 13C6 Leucine; Placebo; Procedure: Brain PET scan; Pyruvate, creatine, niacinamide; RASAGILINE MESILATE; RIVASTIGMINE; Raclopride; Radiopharmaceuticals; Rasagilin; Rasagiline; Riluzole; Rivastigmine; Salsalate; Single dose C2N-8E12; Stem cell therapy; Sugar pill; Suvorexant; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Tideglusib; Tolfenamic Acid; Tolfenamic acid; Trihexyphenidyl; UCB0107 (bepranemab); Ubidecarenon; Valproic acid; Vizamyl; Vizamyl (flutemetamol(F-18)); Water; Xeomin; Zolpidem; [18F]Florbetapir; [18F]MNI-815 (MNI-815); [18F]MNI-952; [18F]MNI-958; [18F]T807 ([18F]MNI-777); [F18]-FDDNP

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005539-10-DE (EUCTR)	29/04/2014	18/12/2013	Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.	Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation	Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury. MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A Trade Name: Xeomin INN or Proposed INN: NT 101 Other descriptive name: BOTULINUM TOXIN TYPE A	Merz Pharmaceuticals GmbH	NULL	Not Recruiting			Female: yes Male: yes	180	Phase 3	United States;Poland;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2012-005539-10-DE
(EUCTR)

29/04/2014

18/12/2013

Clinical study to investigate the efficacy and safety of two dose levels of NT 201 versus placebo in treating chronic troublesome sialorrhea in various neurological conditions.

Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two dose levels of NT 201 in treating chronic troublesome sialorrhea in various neurological conditions - SIAXI – Sialorrhea in Adults Xeomin Investigation

Chronic troublesome sialorrhea resulting from neurological conditions in adults with Parkinson's disease or atypical parkinsonism (multiple system atrophy, corticobasal degeneration or progressive supranuclear palsy), or after stroke or traumatic brain injury.
MedDRA version: 18.1;Level: PT;Classification code 10039424;Term: Salivary hypersecretion;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A
Trade Name: Xeomin
INN or Proposed INN: NT 101
Other descriptive name: BOTULINUM TOXIN TYPE A

Merz Pharmaceuticals GmbH

NULL

Not Recruiting

Female: yes
Male: yes

180

Phase 3

United States;Poland;Germany